Dr Reddy's: Some disappointment in Q4, but generics focus improves outlook

Dr Reddy’s Laboratories (DRL) posted 14 per cent year-on-year (YoY) growth in revenue at Rs 4,016.6 crore and a 44 per cent jump in net profit to Rs 434.3 crore in the March quarter (Q4). The numbers were ahead of Bloomberg consensus estimates of Rs 3,895 crore and Rs 418 crore, respectively. However, there were disappointments, too, including below-par US sales in light of contribution from some special products, a sequential decline in sales across other key geographies, and on the gross margins front.  The overall numbers also included revenue of Rs 180 crore fr.....
Key stories on business-standard.com are available to premium subscribers only.

Already a premium subscriber?

Subscribe to get an across device (Website, Mobile Web, Iphone, Ipad, and Android Phone applications) access to Premium content, Breaking News alerts, Industry Newsletters, Stock and Corporate news alerts, access to Archives and a lot more.